Physician profile
Deborah I Lee
NPI 1225168172
$3,122.18
in general payments reported to CMS, 2019-2025
19 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.44 · 2022: $524 · 2023: $296 · 2024: $918 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,551 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,551.24 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $550.72 | 2022-2025 | Tryptyr, Rocklatan, Eysuvis |
| Abbvie INC. | $500.87 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $438.87 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $432.91 | 2021-2023 | |
| Bausch & Lomb Americas INC. | $240.11 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $208.53 | 2024-2025 | |
| Dompe US, INC. | $200.41 | 2024-2025 | Oxervate |
| Amgen INC. | $84.50 | 2024 | Tepezza |
| Genentech USA, INC. | $65.34 | 2025 | Susvimo, Vabysmo |
| Coopervision INC. | $65.06 | 2023 | Myday Contact Lens, Misight Contact Lens |
| Oyster Point Pharma, INC. | $60.21 | 2022-2023 | Tyrvaya |
| Glaukos Corporation | $59.38 | 2024-2025 | Photrexa, Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Rxsight INC | $49.47 | 2024-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Horizon Therapeutics Plc | $41.35 | 2022 | |
| Astellas Pharma US INC | $35.99 | 2025 | Izervay |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $24.48 | 2022 | |
| Apellis Pharmaceuticals, INC. | $22.82 | 2023 | Syfovre |
| Lkc Technologies, INC. | $21.04 | 2025 | |
| Harrow Eye, LLC | $20.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.